Stocktoria
Merck & Co., Inc. MRK
Merck & Co., Inc. (MRK) earns a Piotroski F-score of 4/9 (mixed financial health). It pays a dividend yielding 2.57% (safety: moderate). FY2025 revenue was $65.0B at a 28.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.27 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-12 | Daiwa Capital | Outperform (up) |
| 2026-08-11 | Argus Research | Buy (main) |
| 2026-08-05 | Guggenheim | Buy (main) |
| 2026-07-29 | Barclays | Overweight (main) |
| 2026-07-13 | JP Morgan | Overweight (main) |
| 2026-07-13 | BMO Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
| ABT | ABBOTT LABORATORIES | 5/9 | 4.85 | 25.1 | +5.7% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
FAQ
Is MRK financially healthy?
Merck & Co., Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does MRK pay a dividend, and is it safe?
Yes. Merck & Co., Inc. pays a dividend yielding about 2.57% with a 44.8% payout ratio, rated “moderate” for safety.
How profitable is MRK?
In FY2025, Merck & Co., Inc. had a net margin of 28.1% and a return on equity of 34.7%.
Is MRK overvalued or undervalued?
Merck & Co., Inc. trades at about 18.3× trailing earnings — below its 10-year norm (10-year range 14.7×–862.7×, median 26.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for MRK?
The average Wall-Street price target for Merck & Co., Inc. is $136.85, about 3.0% above the recent price, from 26 analysts (consensus: buy).
Is MRK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Merck & Co., Inc.: a Piotroski F-score of 4/9, a P/E of about 17.4×, a dividend yield of 2.57%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.